ABBV-3067 + Placebo ABBV-3067 + ABBV-2222 + Placebo ABBV-2222
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Cystic Fibrosis
Conditions
Cystic Fibrosis
Trial Timeline
Dec 11, 2019 → Jun 9, 2022
NCT ID
NCT03969888About ABBV-3067 + Placebo ABBV-3067 + ABBV-2222 + Placebo ABBV-2222
ABBV-3067 + Placebo ABBV-3067 + ABBV-2222 + Placebo ABBV-2222 is a phase 2 stage product being developed by AbbVie for Cystic Fibrosis. The current trial status is completed. This product is registered under clinical trial identifier NCT03969888. Target conditions include Cystic Fibrosis.
What happened to similar drugs?
20 of 20 similar drugs in Cystic Fibrosis were approved
Approved (20) Terminated (7) Active (0)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03969888 | Phase 2 | Completed |
Competing Products
20 competing products in Cystic Fibrosis